PEPTIDEREPORT

FDA · Rulemaking and policy

FDA proposes categories of drug products presenting demonstrable difficulties for compounding

FDA published a proposed rule addressing drug products or categories that present demonstrable difficulties for compounding under sections 503A and 503B. The record is tracked as sector-level policy, not as a company action.

Proposal legal stageMar 19, 2024 record dateUnited States jurisdiction
Open the primary-source record

Record status

Proposed rule

Agency
U.S. Food and Drug Administration
Action
Proposed rule
Stage
Proposal
Last verified
Jul 10, 2026

Source-backed timeline

Status history

  1. Proposed rule publishedSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records